Oral Nalbuphine Extended-Release Is Effective in Severe Prurigo Nodularis–Associated Pruritus: Results From a Phase 2b/3, Double-Blind, Placebo-Controlled Study

Main Article Content

Sonja Ständer
Elke Weisshaar
Jennifer L Parish
Jacek C Szepietowski
Adam Reich
Neil J Korman
Enoch Bortey
Thomas R Sciascia

Keywords

prurigo nodularis, nalbuphine, pruritus, clinical trial

Abstract

N/A

References

1. Elmariah S et al. J Am Acad Dermatol. 2021;84(3):747-760

2. Prurigo Nodularis – Market Insights, Epidemiology, and Market Forecast. Accessed September 14, 2022. https://www.delveinsight.com/report-store/prurigo-nodularis-market

3. Steinke S et al. J Am Acad Dermatol. 2018;79(3):457-463

4. Elmariah S et al. J Am Acad Dermatol. 2021;7:156-163

5. Kim BS et al. Abstract presented at: Winter Clinical Dermatology Conference–Hawaii®; January 16-24, 2021; virtual

6. Drug Enforcement Administration. Nalbuphine hydrochloride. Accessed September 14, 2022. https://www.deadiversion.usdoj.gov/drug_chem_info/nalbuphine.pdf

7. WHO Expert Committee on Drug Dependence. World Health Organ Tech Rep Ser. 1989;775:1-48

8. Weisshaar E et al. J Eur Acad Dermatol Venereol. 2021;36(3):453-461

Most read articles by the same author(s)